Pazdur Questions Safety, Legality of FDA’s Expedited Drug Approvals Programs

Richard Pazdur, the new director of the Center for Drug Evaluation and Research, raised concerns amid the rollout of several FDA initiatives seeking to shorten the drug review process.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top